INCYTE CORP
INCYTE CORP
Action · US45337C1027 · INCY · 896133 (XNAS)
Aperçu Indicateurs financiers
68,77 USD
3,41 % 2,27 USD
NASDAQ (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 20:00

Cours actuels de INCYTE CORP

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
INCY
USD
06.06.2025 20:00
68,77 USD
67,24 USD
+2,28 %
XLON: London
London
0J9P.L
USD
06.06.2025 15:05
67,97 USD
67,24 USD
+1,09 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 5,70 % 15,37 % -1,88 % -9,42 % 16,44 % -26,46 %

Profil de l'entreprise pour INCYTE CORP Action

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Fonds investis

Les fonds suivants ont investi dans : INCYTE CORP investi :

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millions
562,22
Part (%)
1,32 %
Fonds
iShares MSCI World Health Care Sector UCITS ETF USD (Dist)
Vol. en millions
659,98
Part (%)
0,18 %
Fonds
iShares Edge MSCI World Minimum Volatility UCITS ETF USD (Dist)
Vol. en millions
3,86
Part (%)
0,14 %
Fonds
iShares Edge MSCI World Minimum Volatility UCITS ETF EUR Hedged (Acc)
Vol. en millions
147,77
Part (%)
0,14 %
Fonds
iShares Nasdaq 100 UCITS ETF EUR Hedged (Acc)
Vol. en millions
214,38
Part (%)
0,12 %

Données de l'entreprise

Nom INCYTE CORP
Société Incyte Corporation
Symbole INCY
Site web https://www.incyte.com
Marché d'origine XNAS NASDAQ
WKN 896133
ISIN US45337C1027
Type de titre Action
Secteur Healthcare
Industrie Medical - Pharmaceuticals
PDG Mr. Herve Hoppenot
Capitalisation boursière 11 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 2,6 T
Adresse 1801 Augustine Cut-Off, 19803 Wilmington
Date d'introduction en bourse 2018-01-29

Fractionnements d'actions

Date Fractionnement
01.09.2000 2:1
10.11.1997 2:1

Symboles boursiers

Nom Symbole
Frankfurt ICY.F
London 0J9P.L
NASDAQ INCY

Autres actions

Les investisseurs qui détiennent INCYTE CORP ont également les actions suivantes dans leur portefeuille :
AMGEN INC
AMGEN INC Action
AUTODESK INC
AUTODESK INC Action
BIOGEN INC
BIOGEN INC Action
BRUNSWICK EXPLORAT. INC.
BRUNSWICK EXPLORAT. INC. Action
CISCO SYSTEMS INC
CISCO SYSTEMS INC Action
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Action
ILLUMINA INC
ILLUMINA INC Action
INTEL CORP
INTEL CORP Action
ISDB TR.S.2 24/29 MTN
ISDB TR.S.2 24/29 MTN Obligation
MICROSOFT CORP
MICROSOFT CORP Action
TERUMO CORP
TERUMO CORP Action
UNDER ARMOUR A DL-,000333
UNDER ARMOUR A DL-,000333 Action
VERTEX PHARMACEUTICALS INC
VERTEX PHARMACEUTICALS INC Action
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025